Description

Retatrutide (rDNA origin) for Injection 10 mg is a next-generation, investigational peptide-based therapy engineered using recombinant DNA technology. It is designed to target multiple metabolic pathways through a triple agonist mechanism, acting on GLP-1, GIP, and glucagon receptors. This multimodal approach aims to deliver enhanced efficacy in metabolic regulation compared to single-pathway therapies.

Key Features:

• Advanced Triple Agonist Action: Simultaneously targets GLP-1, GIP, and glucagon receptors to support improved glycemic control, energy expenditure, and weight management.
• Recombinant DNA Technology: Manufactured using high-precision rDNA processes to ensure consistency, purity, and biological activity.
• Optimized Dosage Strength: Each vial contains 10 mg of Retatrutide, formulated for controlled and precise administration.
• Metabolic Health Focus: Developed for use in managing conditions such as obesity and type 2 diabetes, under clinical evaluation.